<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976182</url>
  </required_header>
  <id_info>
    <org_study_id>LGL</org_study_id>
    <nct_id>NCT01976182</nct_id>
  </id_info>
  <brief_title>Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia</brief_title>
  <official_title>Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LGL leukemia represents a rare subtype of chronic T or NK lymphoproliferative disorders. It
      is an indolent disease, the main hematological or autoimmune complications lead to a
      treatment in more than 60% of patients.

      Investigators set up at the University Hospital of Rennes, a database of more than 300
      patients with LGL leukemia from major French services that support this disease, and
      published in 2010 the largest series of patients in the world (n = 229). However, the limited
      heterogeneity and retrospective data collected, as all previously released, makes it
      difficult the proposal of consensual treatment options. If first and second line treatments
      are based on the use of immunosuppression with methotrexate, cyclophosphamide, or cyclosporin
      A, no molecule has proven superiority over others. Methotrexate and cyclophosphamide are
      mainly used in the first line. Invetigators just have in the literature data on about 100
      patients treated with either of these drugs. Combining the results of our series with those
      in the literature, invetigators estimate the respective overall response rate (RG) and
      complete response rate (CR) in 55% and 30% for methotrexate, and 60% and 50% for
      cyclophosphamide.

      Thus, there are four objective in this study :

        1. to compare the respective efficacies of methotrexate and cyclophosphamide when
           administered as first-line therapies in patients suffering from T/NK LGL leukemia with
           severe neutropenia or neutropenia associated with infections, and/or anemia requiring
           transfusions, and/or auto-immune associated disease

        2. to evaluate the percentage of patients refractory to methotrexate or cyclophosphamide
           for which a second line treatment is efficacious

        3. to explore, in case of non-response to the first-line therapy, the efficacy of
           ciclosporine A, the comparison being performed with the treatment which was not
           administered in the first-line therapy

        4. to evaluate the response rate according to the phenotypic subtype of LGL leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large Granular Lymphocyte (LGL) leukemia is a clonal disorder involving tissue invasion of
      marrow, spleen and liver. Clinical presentation is dominated by recurrent infections
      associated with neutropenia, anemia, splenomegaly, and auto-immune diseases, particularly
      rheumatoid arthritis. Both T cell and NK cell subtypes of LGL leukemia are indolent disease
      and considered as a chronic illness and lead to a treatment in more than 60% of patients.

      LGL leukemia displays a chronic clinical course. Recommendations regarding therapy are
      similar for both subtypes. Indications for treatment include 1) severe neutropenia (ANC &lt;500
      mm3); 2) neutropenia (ANC &lt;1500mm3) with symptomatic recurrent infections; 3) symptomatic or
      transfusion-dependent anemia and 4) associated autoimmune conditions requiring therapy, most
      often rheumatoid arthritis.

      There is no standard treatment for patients with LGL leukemia. The numerous case reports
      published do not provide a consensus for a particular treatment. All the six largest series
      published in the literature so far (collecting data on more than 40 patients) are
      retrospective.

      Immunosuppressive therapy remains the foundation of treatment including single three agents
      i.e. methotrexate, oral cyclophosphamide and ciclosporin A. However prospective trials
      involving large numbers of patients have not been performed and no molecule has proven
      superiority over others.

      Invetigators set up at the University Hospital of Rennes, a database of more than 300
      patients with LGL leukemia from major French services that support this disease, and
      published in 2010 the largest series of patients in the world (n = 229). However, the limited
      heterogeneity and retrospective data collected, as all previously released, makes it
      difficult the proposal of consensual treatment options. Combining the results of our series
      with those of the literature, invetigators estimate that overall response rate and complete
      response rate are 55% and 30% with methotrexate, 60% and 50% with cyclophosphamide, and 55%
      and less than 20% with ciclosporine A, respectively.

      Thus, there are four objective in this study :

        1. to compare the respective efficacies of methotrexate and cyclophosphamide when
           administered as first-line therapies in patients suffering from T/NK LGL leukemia with
           severe neutropenia or neutropenia associated with infections, and/or anemia requiring
           transfusions, and/or auto-immune associated disease

        2. to evaluate the percentage of patients refractory to methotrexate or cyclophosphamide
           for which a second line treatment is efficacious

        3. to explore, in case of non-response to the first-line therapy, the efficacy of
           ciclosporine A, the comparison being performed with the treatment which was not
           administered in the first-line therapy

        4. to evaluate the response rate according to the phenotypic subtype of LGL leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>at Month 4</time_frame>
    <description>The main endpoint will be the hematological CR rate evaluated after 4 months of treatment (binary endpoint). Complete response (CR) is defined as a normalization of clinical examination (disappearance of splenomegaly) and a complete normalization of blood counts (i.e., hemoglobin &gt;12g/dL, platelets &gt;150x109/L, ANC &gt;1.5x109/L), lymphocytosis &lt;4x109/L and circulating LGL in the normal range (&lt;0.3x109/L). The number of LGL will be quantitated on blood smears.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>at Month 4, and at Month 8 and Month 12 in non-responders at Month 4</time_frame>
    <description>Hematological overall response rate (ORR) defined as the sum of complete responses and partial responses over the total number of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>at Month 8 and Month 12</time_frame>
    <description>Complete response (CR) is defined as a normalization of clinical examination (disappearance of splenomegaly) and a complete normalization of blood counts (i.e., hemoglobin &gt;12g/dL, platelets &gt;150x109/L, ANC &gt;1.5x109/L), lymphocytosis &lt;4x109/L and circulating LGL in the normal range (&lt;0.3x109/L). The number of LGL will be quantitated on blood smears.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological partial response (PR)</measure>
    <time_frame>at Month 4, Month 8 and Month 12</time_frame>
    <description>Hematological partial response (PR) defined as an improvement in blood counts which do not meet criteria for complete remission (e.g., ANC increasing more than 50% and reaching more than 0.5 but less than 1.5x109/L with non-recurrence of infections, or hemoglobin level increasing more than 2 g/dL from baseline and transfusion requirements stopping without normalization of the hemoglobin level defined as hemoglobin &gt;12g/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disease</measure>
    <time_frame>at Month 4, Month 8 and Month 12</time_frame>
    <description>Progressive disease defined as worsening of cytopenia or organomegaly or incidence of infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-relapse</measure>
    <time_frame>from Month 4 to endpoint (in first-line treatment responders)</time_frame>
    <description>Time-to-relapse (censored variable). Relapse is defined as re-occurrence of either neutropenia or anemia (ANC &lt;1x109/L and/or hemoglobin &lt;10g/dL) or clonal LGL &gt;0.5x109/L in complete responders, or as a return to baseline values of either ANC or hemoglobin in partial responders, at two monthly consecutive blood tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-relapse</measure>
    <time_frame>from Month 8 to endpoint (in second-line treatment responders)</time_frame>
    <description>Time-to-relapse (censored variable). Relapse is defined as re-occurrence of either neutropenia or anemia (ANC &lt;1x109/L and/or hemoglobin &lt;10g/dL) or clonal LGL &gt;0.5x109/L in complete responders, or as a return to baseline values of either ANC or hemoglobin in partial responders, at two monthly consecutive blood tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular remission</measure>
    <time_frame>at Month 4 and Month 12 for hematological complete responders</time_frame>
    <description>Molecular remission defined as the disappearance of the clonal pattern of TCR gamma multiplex rearrangement and Phenotypic remission is defined as :
For the T subtype: disappearance of the excess of CD3+/CD8+ cells (or disappearance of the LGL clone according to the specific subtype observed at inclusion);
For the NK subtype: disappearance of the excess of CD3-/CD56+ cells (or disappearance of the LGL clone according to the specific subtype observed at inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>Month 2, Month 4, Month 6, Month 8, Month 10, Month 12</time_frame>
    <description>Adverse events rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Month 2, Month 4, Month 6, Month 8, Month 10, Month 12</time_frame>
    <description>Compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between the response to treatment and the phenotypic subtype</measure>
    <time_frame>Day 1</time_frame>
    <description>Identification of a relationship between the response to treatment and the phenotypic subtype characterized by the panel of monoclonal antibodies defined in the ancillary study subsection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Large Granular Lymphocytes Leukemia</condition>
  <arm_group>
    <arm_group_label>METHOTREXATE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take
In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.
Non responders at Month 4 will be randomized and treated either by:
Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;
Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYCLOPHOSPHAMIDE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.
In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);
Non responders at Month 4 will be randomized and treated either by:
Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;
Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.</description>
    <arm_group_label>METHOTREXATE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.</description>
    <arm_group_label>CYCLOPHOSPHAMIDE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Common criteria of LGL leukemia: the diagnosis is based on a chronic LGL peripheral
             blood expansion (&gt;0.5x109/L), usually lasting more than 6 months

          -  Specific criteria for T-LGL leukemia or NK-LGL lymphocytosis or chronic NK-LGL
             leukemia:

               -  Specific criteria for T-LGL leukemia:

          -  Expression of LGL surface markers compatible with an activated T-cell (commonly
             alpha-beta+/CD3+/CD8+/CD57+ and/or CD16+) phenotype or gamma-delta+ T cells;

          -  Clonal rearrangement of TCRγ gene using PCR or specific and clonal Vβ expression using
             FCM.

               -  Specific criteria for NK-LGL lymphocytosis or chronic NK LGL leukemia:

          -  Expression of LGL surface markers compatible with a NK cell (commonly CD3-/CD8+/CD16+
             and/or CD16+/CD56+) phenotype;

          -  CD56+ or CD16+ NK cells greater than 0.75x109/L;

          -  The term of chronic NK-LGL lymphocytosis is used for patients with chronic illness
             (NB: patients with massive tissue LGL infiltration of the spleen, liver and bone
             marrow and presenting aggressive clinical behavior are considered as having aggressive
             NK-LGL leukemia and should not be included).

          -  Age above 18 years

          -  ECOG performance status of 0-2

          -  Life expectancy of at least 1 year

          -  Lack of previous treatment (except with G-CSF or transfusions)

          -  At least one indication of treatment:

               -  Isolated severe neutropenia (ANC &lt;0.5x109/L) or neutropenia (ANC &lt;1.5x109/L) with
                  two or more infections requiring antibiotics;

               -  Anemia (whatever the underlying mechanism: pure red cell aplasia or marrow
                  infiltration) requiring transfusions greater than 2 units for two months prior to
                  inclusion, or symptomatic anemia (hemoglobin &lt;10g/dl) with impairment of the
                  quality of life;

               -  Associated complications such as systemic diseases or auto-immune diseases (i.e.
                  recurrent uveitis, cutaneous vasculitis, autoimmune hemolytic anemia, idiopathic
                  thrombocytopenic purpura, rheumatoid arthritis resistant to steroids and/or
                  immunomodulator agents (colchicin, disulone, hydrochloroquine)) and justifying a
                  treatment with methotrexate or cyclophosphamide

          -  Written informed consent

        Exclusion Criteria:

          -  Inability to understand or to follow study procedures

          -  Prior or concurrent malignancy within the past 5 years except inactive nonmelanomatous
             skin cancer or carcinoma in situ of the cervix

          -  Other serious medical illnesses, such as hepatic, renal, cardiac, pulmonary,
             neurologic, or metabolic disease that would preclude the patient's ability to tolerate
             methotrexate, cyclophosphamide, or ciclosporine A

          -  Reactive LGL lymphocytosis (i.e. after viral infection)

          -  ALAT/ASAT or alkalin phosphatases &gt;3 times normal values

          -  Creatinine clairance &lt;50 ml/min

          -  Serologic evidence of HIV, hepatitis C or hepatitis B infection

          -  Non effective contraception

          -  Positive pregnancy test

          -  Nursing woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thierry Lamy, PUPH</last_name>
    <phone>02 99 28 42 91</phone>
    <phone_ext>+33</phone_ext>
    <email>thierry.lamy@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno ROYER, MD</last_name>
      <phone>03 22 45 59 14</phone>
      <phone_ext>+33</phone_ext>
      <email>royer.bruno@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Royer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata truchand-Graczyk, MD</last_name>
      <phone>02 41 35 45 24</phone>
      <phone_ext>+33</phone_ext>
      <email>MaTruchan@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Malgorazata Truchand-Graczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intern medecine Service - CH Antibes-Juan-les-Pins</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel RE, MD</last_name>
      <phone>04 97 24 77 46</phone>
      <phone_ext>+33</phone_ext>
      <email>daniel.re@ch-antibes.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel RE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hacène ZERAZHI, MD</last_name>
      <phone>04 32 75 93 93</phone>
      <phone_ext>+33</phone_ext>
      <email>hzerazhi@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Zerazhi Hacène, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH de la cote basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Banos, MD</last_name>
      <phone>05 59 44 38 32</phone>
      <phone_ext>+33</phone_ext>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Banos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology service - CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustapha Ghomari, MD</last_name>
      <phone>03 44 11 23 90</phone>
      <phone_ext>+33</phone_ext>
      <email>kamel.ghomari@ch-beauvais.fr</email>
    </contact>
    <investigator>
      <last_name>Mustapha Ghomari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie BRION, MD</last_name>
      <phone>03 81 66 82 32</phone>
      <phone_ext>+33</phone_ext>
      <email>abrion@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Annie BRION, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Beziers</name>
      <address>
        <city>Beziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain SAAD, MD</last_name>
      <phone>04 67 35 70 63</phone>
      <phone_ext>+33</phone_ext>
      <email>alain.saad@ch-beziers.fr</email>
    </contact>
    <investigator>
      <last_name>Alain SAAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - HOpital Avicienne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Cymbalista, MD</last_name>
      <phone>01 48 95 56 40</phone>
      <phone_ext>+33</phone_ext>
      <email>florence.cymbalista@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Cymbalista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Docteur Duchenne</name>
      <address>
        <city>Boulogne sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bachra CHOUFI, MD</last_name>
      <phone>03 21 99 82 02</phone>
      <phone_ext>+33</phone_ext>
      <email>b.choufi@ch-boulogne.fr</email>
    </contact>
    <investigator>
      <last_name>Bachra CHOUFI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussam SAAD, MD</last_name>
      <phone>02 98 22 34 21</phone>
      <phone_ext>+33</phone_ext>
      <email>hussam.saad@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>hussam SAAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre VILQUE, MD</last_name>
      <phone>02 31 45 50 12</phone>
      <phone_ext>+33</phone_ext>
      <email>jp.vilque@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre VILQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris BIENVENU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology Service - CH Louis Pasteur</name>
      <address>
        <city>Chartres</city>
        <zip>28018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>michel maigre, MD</last_name>
      <phone>02 37 30 30 77</phone>
      <phone_ext>+33</phone_ext>
      <email>mmaigre@ch-chartres.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Maigre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology Service - CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Tournilhac, MD</last_name>
      <phone>04 73 75 00 65</phone>
      <phone_ext>+33</phone_ext>
      <email>otournilhac@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Joel Fleury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Tournilhac, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - Civils hospital</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Belkaid, MD</last_name>
      <phone>03 89 12 43 29</phone>
      <phone_ext>+33</phone_ext>
      <email>mohammed.belkaid@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>Mohammed BELKAID, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service CHSF</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Célia SALANOUBAT, MD</last_name>
      <phone>01 60 90 31 78</phone>
      <phone_ext>+33</phone_ext>
      <email>celia.salanoubat@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Célia SALANOUBAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor Lymphoid Hemopathy Unit</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jehan DUPUIS, MD</last_name>
      <phone>01 49 81 41 74</phone>
      <phone_ext>+33</phone_ext>
      <email>jehan.dupuis@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jehan DUPUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc MICHEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Hematology Unit</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle FERRANT, MD</last_name>
      <phone>03 80 29 50 41</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuelle.ferrant@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle FERRNAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH Michalon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lysiane MOLINA, MD</last_name>
      <phone>04 76 76 76 69</phone>
      <phone_ext>+33</phone_ext>
      <email>lmolina@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Lysiane Molina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mourad TIAB, MD</last_name>
      <phone>02 51 44 61 73</phone>
      <phone_ext>+33</phone_ext>
      <email>mourad.tiab@chd.vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Mourad TIAB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH LE MANS</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Laribi, MD</last_name>
      <phone>02 43 43 29 59</phone>
      <phone_ext>+33</phone_ext>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel Laribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno CAZIN, MD</last_name>
      <phone>03 20 44 42 90</phone>
      <phone_ext>+33</phone_ext>
      <email>b-cazin@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Cazin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Bordessoule, MD</last_name>
      <phone>05 55 05 66 42</phone>
      <phone_ext>+33</phone_ext>
      <email>bordessoule.urch@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Bordessoule, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regis Costello, MD</last_name>
      <phone>04 91 38 41 50</phone>
      <phone_ext>+33</phone_ext>
      <email>regis.costello@free.fr</email>
    </contact>
    <investigator>
      <last_name>Regis Costello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thérèse Aurran-Schleinitz, MD</last_name>
      <phone>04 91 22 38 66</phone>
      <phone_ext>+33</phone_ext>
      <email>aurrant@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Thérèse Aurran-Schleinitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome REY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wajed Abarah, MD</last_name>
      <phone>01 64 35 38 75</phone>
      <phone_ext>+33</phone_ext>
      <email>w-abarah@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Wajed Abarah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH Notre Dame Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Guibaud, MD</last_name>
      <phone>03 87 55 32 32</phone>
      <phone_ext>+33</phone_ext>
      <email>i.guibaud@chr-metz-thionville.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Guibaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematogy Unit CHU ST ELOI</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON, MD</last_name>
      <phone>04 67 33 83 62</phone>
      <phone_ext>+33</phone_ext>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume CARTRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH E.MULLER</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard DRENOU, MD</last_name>
      <phone>03 89 64 77 85</phone>
      <phone_ext>+33</phone_ext>
      <email>drenoub@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard DRENOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - CHU Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice MAHE, MD</last_name>
      <phone>02 40 08 32 54</phone>
      <phone_ext>+33</phone_ext>
      <email>beatrice.mahe@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Beatrice MAHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Unit CH Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel RE, MD</last_name>
      <phone>04 92 03 16 18</phone>
      <phone_ext>+33</phone_ext>
      <email>daniel.re@ch-antibes.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel RE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology Unit CHU Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric JOURDAN, MD</last_name>
      <phone>04 66 68 32 31</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Jourdan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - CHR Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda ALEXIS, MD</last_name>
      <phone>02 38 22 95 47</phone>
      <phone_ext>+33</phone_ext>
      <email>magda.alexis@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Magda ALEXIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - Hopital La Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique LEBLOND, MD</last_name>
      <phone>01 42 16 28 24</phone>
      <phone_ext>+33</phone_ext>
      <email>veronique.leblond@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique LEBLOND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain CHOQUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Hopital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François DREYFUS, MD</last_name>
      <phone>01 42 34 87 65</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.dreyfus@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>François DREYFUS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne VEKHOFF, MD</last_name>
      <phone>01 49 28 34 29</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-vekhoff@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne VEKHOFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc ZINI, MD</last_name>
      <phone>01 42 49 92 97</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-marc.zini@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc ZINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit Hopital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SANHES, MD</last_name>
      <phone>04 68 61 64 48</phone>
      <phone_ext>+33</phone_ext>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence SANHES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service- CH Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Sarah Dilhuydy, MD</last_name>
      <phone>05 57 65 65 11</phone>
      <phone_ext>+33</phone_ext>
      <email>marie-sarah.dilhuydy@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Sarah DILHUYDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François VIALLARD, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH LYON SUD</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie Michallet, MD</last_name>
      <phone>04 78 86 43 05</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-sophie.michallet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Sophie Michallet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile TOMOWIAC, MD</last_name>
      <phone>05 49 44 43 07</phone>
      <phone_ext>+33</phone_ext>
      <email>c.tomowiac@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile TOMOWIAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH René DUBOS</name>
      <address>
        <city>Pontoise</city>
        <zip>95000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo GONZALEZ, MD</last_name>
      <phone>01 30 75 47 35</phone>
      <phone_ext>+33</phone_ext>
      <email>hugo.gonzalez@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Hugo GONZALEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy - Hematology Service</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique orsini-piocelle, MD</last_name>
      <phone>04 50 63 66 08</phone>
      <phone_ext>+33</phone_ext>
      <email>forsinipiocelle@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Frédérique Orsini-Piocelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit- Hopital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain DELMER, MD</last_name>
      <phone>03 26 78 36 44</phone>
      <phone_ext>+33</phone_ext>
      <email>adelmer@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DELMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CHU of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lamy, PUPH</last_name>
      <phone>02 99 28 42 91</phone>
      <phone_ext>+33</phone_ext>
      <email>thierry.lamy@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lamy, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - CH Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane LEPETRE, MD</last_name>
      <phone>02 32 08 22 23</phone>
      <phone_ext>+33</phone_ext>
      <email>stelep@rouen.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane LEPETRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Unit - Institut de cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>60008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine AUGEUL-MEUNIER, MD</last_name>
      <phone>04 77 91 70 60</phone>
      <phone_ext>+33</phone_ext>
      <email>karine.augeul-meunier@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Karine AUGEUL-MEUNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Quentin Oncohematology</name>
      <address>
        <city>Saint Quentin</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda GARIDI, MD</last_name>
      <phone>03 23 06 78 61</phone>
      <phone_ext>+33</phone_ext>
      <email>r.garidi@ch-stquentin.fr</email>
    </contact>
    <investigator>
      <last_name>Reda GARIDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic YSEBAERT, MD</last_name>
      <phone>05 61 77 76 68</phone>
      <phone_ext>+33</phone_ext>
      <email>ysebaert.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Loic YSEBEART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel ADOUE, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline DARTIGAS, MD</last_name>
      <phone>02 47 47 37 12</phone>
      <phone_ext>+33</phone_ext>
      <email>c.dartigeas@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline DARTIGAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit Hopitaux de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER, MD</last_name>
      <phone>03 83 15 32 82</phone>
      <phone_ext>+33</phone_ext>
      <email>p.feugier@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intern Medecine Unit CHBA</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry JARDEL, MD</last_name>
      <phone>02 97 01 41 45</phone>
      <phone_ext>+33</phone_ext>
      <email>henry.jardel@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Henry JARDEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>large granular lymphocytes leukemia</keyword>
  <keyword>immunosuppressive drugs</keyword>
  <keyword>methotrexate</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>efficiency</keyword>
  <keyword>phase II randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

